At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,205 enrolled
Drug / intervention
sunitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Patterns With Targeted Therapies in Metastatic Renal Cell Carcinoma (mRCC) in Sweden - A Retrospective Analysis of Data From National Registries
In Brief
An observational study evaluating sunitinib and axitinib for Kidney Neoplasms. Completed, enrolled 1,205 participants across 1 site.
Detailed Summary
The objectives of this study is to investigate treatment patterns and outcomes for Sutent and Inlyta in mRCC patients in a nationwide population-based setting in Sweden.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Neoplasms
CountriesSweden
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartJan 2021
Primary CompletionJul 2021
Study CompletionMar 2022
TodayJul 2026
First PostedDec 16, 2020
Enrollment StartJan 20, 2021
Primary CompletionJul 31, 2021
Study CompletionMar 18, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.5 years ago
Interventions
sunitinibdrug
As provided in real world
axitinibdrug
As provided in real world